Five patients with malignant endocrine tumors treated with imatinib mesylate (Glivec®)

Authors

  • Henrik Kindmark Department of Medicine/Endocrine Oncology, University Hospital, Uppsala, Sweden
  • Eva Tiensuu Janson Department of Medicine/Endocrine Oncology, University Hospital, Uppsala, Sweden
  • Bengt Gustavsson Novartis, Sweden
  • Camilla Eriksson Novartis, Sweden
  • Gunnel Larsson Department of Medicine/Endocrine Oncology, University Hospital, Uppsala, Sweden
  • Dan Granberg Department of Medicine/Endocrine Oncology, University Hospital, Uppsala, Sweden
  • Gordana Kozlowacki Department of Medicine/Endocrine Oncology, University Hospital, Uppsala, Sweden
  • Britt Skogseid Department of Medicine/Endocrine Oncology, University Hospital, Uppsala, Sweden
  • Staffan Welin Department of Medicine/Endocrine Oncology, University Hospital, Uppsala, Sweden
  • Kjell Öberg Department of Medicine/Endocrine Oncology, University Hospital, Uppsala, Sweden
  • Barbro Eriksson Department of Medicine/Endocrine Oncology, University Hospital, Uppsala, Sweden

DOI:

https://doi.org/10.3109/02841860902897707

Abstract

No abstract available

Downloads

Download data is not yet available.

Downloads

Published

2010-01-01

How to Cite

Kindmark, H., Tiensuu Janson, E., Gustavsson, B., Eriksson, C., Larsson, G., Granberg, D., … Eriksson, B. (2010). Five patients with malignant endocrine tumors treated with imatinib mesylate (Glivec®). Acta Oncologica, 49(1), 100–101. https://doi.org/10.3109/02841860902897707

Issue

Vol. 49 No. 1 (2010): Acta Oncologica

Section

Articles